Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ North Carolina State, Liquidia Technologies IncfiledCriticalUniv North Carolina State
Priority claimed from PCT/US2006/023722external-prioritypatent/WO2007024323A2/en
Publication of BRPI0611827A2publicationCriticalpatent/BRPI0611827A2/en
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents
(AREA)
Abstract
MÉTODOS, SISTEMAS E MATERIAIS DE FABRICAÇçO DE NANOPARTÍCULA. Nanopartículas são moldadas em moldes de escala nano fabricados de materiais poliméricos de baixa energia de superfície incapazes de serem umedecido. As nanopartículas podem incluir composições farmacêuticas, taggants, agentes de contraste, medicamentos biológicos, composições de medicamento, materiais orgânicos e outros. Os moldes podem ser virtualmente qualquer formato de menos que 10 mícrons em um diâmetro transverso.METHODS, SYSTEMS AND MATERIALS FOR MANUFACTURING NANOParticles. Nanoparticles are molded into nano-scale molds made of low-surface, non-wetting polymeric materials. Nanoparticles may include pharmaceutical compositions, taggants, contrast agents, biological drugs, drug compositions, organic materials and the like. The molds can be virtually any shape of less than 10 microns in a transverse diameter.
BRPI0611827-5A2005-06-172006-06-19
Nanoparticle manufacturing methods, systems and materials
BRPI0611827A2
(en)
Process for encapsulating biologically active agents in a particulate carrier, comprising solubilizing in a hydrophobic ion pairing agent and a solvent, dissolving, emulsifying, and obtaining the carrier; vehicle in the form of particles; and pharmaceutical composition comprising the vehicle.
COMPOSITION AND METHOD FOR THE PREPARATION OF A NANOPARTICULATE cephalosporin, FOR THE TREATMENT OF BACTERIAL DISEASE AND FOR THE PREVENTION AND/OR TREATMENT OF OSTEOPOROSIS